| Drug General Information |
| Drug ID |
D02JDL
|
| Drug Name |
Porfimer Sodium
|
| Synonyms |
Photofrin; Photofrin
|
| Indication |
Non-small cell lung cancer [ICD10:C33-C34]
|
Approved |
[1]
|
|---|
| Company |
Concordia Laboratories Inc
|
| Target and Pathway |
| Target(s) |
Low-density lipoprotein receptor |
Target Info |
Modulator |
[2]
|
|---|
|
KEGG Pathway
|
Endocytosis
|
|
Ovarian steroidogenesis
|
|
Bile secretion
|
|
Toxoplasmosis
|
|
Hepatitis C
|
|
NetPath Pathway
|
FSH Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
Reactome
|
LDL-mediated lipid transport
|
|
Chylomicron-mediated lipid transport
|
|
Retinoid metabolism and transport
|
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
|
Statin Pathway
|
|
Wnt Signaling Pathway
|
|
Wnt Signaling Pathway and Pluripotency
|
|
Visual phototransduction
|
|
Lipid digestion, mobilization, and transport
|
|
Oncostatin M Signaling Pathway
|
|
SREBF and miR33 in cholesterol and lipid homeostasis
|
|
SREBP signalling
|
|
Folate Metabolism
|
|
Vitamin B12 Metabolism
|
|
Selenium Micronutrient Network
|
| References |
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
|---|
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. |
|---|
